Skip to main content

Advertisement

SpringerLink
Log in

Rapid Development of Omentum Metastasis Following Stereotactic Body Radiotherapy (Sbrt) to Para-Aortic Lymph Nodes from Colon Cancer

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Min BS, Kim NK, Sohn SK, Cho CH, Lee KY, Baik SH. Isolated paraaortic lymph-node recurrence after the curative resection of colorectal carcinoma. J Surg Oncol. 2008;97(2):136–40. doi:10.1002/jso.20926. http://doi.wiley.com/10.1002/jso.20926.

    Article  PubMed  Google Scholar 

  2. Lipshitz J, Astrow AB, Xu Y. A unique and as yet unexplored subset of metastatic colorectal cancer: widespread lymph-node-only recurrence. J Gastrointest Cancer. 2013;44(4):466–71. doi:10.1007/s12029-012-9470-6. http://link.springer.com/10.1007/s12029-012-9470-6.

    Article  PubMed  Google Scholar 

  3. Gagnière J, Dupré A, Chabaud S, Peyrat P, Meeus P, Rivoire M. Retroperitoneal nodal metastases from colorectal cancer: curable metastases with radical retroperitoneal lymphadenectomy in selected patients. Eur J Surg Oncol. 2015;41(6):731–7. doi:10.1016/j.ejso.2015.03.229. http://www.sciencedirect.com/science/article/pii/S0748798315003649.

    Article  PubMed  Google Scholar 

  4. Indrani Subarna Bhattacharya, David Woolf, Robert Hughes, Mark Harrison. Stereotactic body radiotherapy (SBRT) in difficult-to-treat areas (para-aortic lymphadenoapthy and pelvic recurrence) in oligometastatic colorectal carcinoma. J Clin Oncol 33, 2015 (suppl 3; abstr 733) http://meetinglibrary.asco.org/content/139125-158

  5. Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30. doi:10.1080/02841860600904854. http://www.ncbi.nlm.nih.gov/pubmed/16982546.

    Article  PubMed  Google Scholar 

  6. Kim M-S, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gastroenterol. 2009;15(48):6091–5. doi:10.3748/wjg.15.6091. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2797667&tool=pmcentrez&rendertype=abstract.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Shibata D, Paty PB, Guillem JG, Wong WD, Cohen AM. Surgical management of isolated retroperitoneal recurrences of colorectal carcinoma. Dis Colon Rectum. 2002;45(6):795–801. doi:10.1007/s10350-004-6300-3. http://www.ncbi.nlm.nih.gov/pubmed/12072633.

    Article  PubMed  Google Scholar 

  8. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18. doi:10.1056/NEJMoa1403108. http://www.nejm.org/doi/abs/10.1056/NEJMoa1403108.

    Article  PubMed  Google Scholar 

  9. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6. doi:10.1200/JCO.2006.09.0928. http://www.jco.org/cgi/doi/10.1200/JCO.2006.09.0928.

    Article  CAS  PubMed  Google Scholar 

  10. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9. doi:10.1200/JCO.2007.14.9930. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2007.14.9930.

    Article  CAS  PubMed  Google Scholar 

  11. Tol J, Koopman M, Cats A, et al. Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer. 2009;Vol 360. doi:10.1056/NEJMoa0808268. http://www.nejm.org/doi/abs/10.1056/NEJMoa0808268

  12. Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet Oncol. 2010;11(9):845–52. doi:10.1016/S1470-2045(10)70175-3. http://linkinghub.elsevier.com/retrieve/pii/S1470204510701753.

    Article  CAS  PubMed  Google Scholar 

  13. Abdalla EK, Vauthey J-N, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–27. doi:10.1097/01.sla.0000128305.90650.71. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356290/.

    Article  PubMed  PubMed Central  Google Scholar 

  14. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg. 1992;53(5):780–5. doi:10.1016/0003-4975(92)91435-C. discussion 785–786http://www.ncbi.nlm.nih.gov/pubmed/1570970.

    Article  CAS  PubMed  Google Scholar 

  15. Kim M-S, Choi C, Yoo S, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. Jpn J Clin Oncol. 2008;38(10):695–700. doi:10.1093/jjco/hyn083. http://www.ncbi.nlm.nih.gov/pubmed/18723850.

    Article  PubMed  Google Scholar 

  16. Mantel F, Flentje M, Guckenberger M. Stereotactic body radiation therapy in the re-irradiation situation—a review. Radiat Oncol. 2013;8(1):7. doi:10.1186/1748-717X-8-7. http://www.ncbi.nlm.nih.gov/pubmed/23289496.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Seo YS, Kim MS, Yoo HJ, Jang W. Il. Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer. World J Gastroenterol. 2014;20(8):2005–13. doi:10.3748/wjg.v20.i8.2005. http://www.ncbi.nlm.nih.gov/pubmed/24587675.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. J Clin Oncol. 2013;31(11):1384–90. doi:10.1200/JCO.2012.45.9651. http://www.ncbi.nlm.nih.gov/pubmed/23460715.

    Article  CAS  PubMed  Google Scholar 

  19. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579–91. doi:10.1038/nrc2403. http://www.ncbi.nlm.nih.gov/pubmed/18596824.

    Article  CAS  PubMed  Google Scholar 

  20. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7(9):987–9. doi:10.1038/nm0901-987. http://www.ncbi.nlm.nih.gov/pubmed/11533692.

    Article  CAS  PubMed  Google Scholar 

  21. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10(2):145–7. doi:10.1038/nm988. http://www.ncbi.nlm.nih.gov/pubmed/14745444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29–37. doi:10.1016/S1470-2045(12)70477-1. http://www.ncbi.nlm.nih.gov/pubmed/23168366.

    Article  CAS  PubMed  Google Scholar 

  23. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506. doi:10.1200/JCO.2012.42.8201. http://www.ncbi.nlm.nih.gov/pubmed/22949147.

    Article  PubMed  Google Scholar 

  24. Josep Tabernero, Allen Lee Cohn, et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol. 33, 2015 (suppl 3; abstr 512). http://meetinglibrary.asco.org/content/138411-158

Download references

Acknowledgment

No funding was obtained.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY, USA

    Sudhamshi Toom

  2. Division of Hematology and Oncology, Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY, USA

    Yiqing Xu

  3. Clinical Medicine, Division of Hematology and Oncology, Department of Internal Medicine, Albert Einstein Medical College, Maimonides Medical Center, 6300 8th Avenue, Brooklyn, 11220, NY, USA

    Yiqing Xu

Authors
  1. Sudhamshi Toom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yiqing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yiqing Xu.

Additional information

Authors have equal contribution in the case report preparation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toom, S., Xu, Y. Rapid Development of Omentum Metastasis Following Stereotactic Body Radiotherapy (Sbrt) to Para-Aortic Lymph Nodes from Colon Cancer. J Gastrointest Canc 49, 190–194 (2018). https://doi.org/10.1007/s12029-016-9858-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-016-9858-9

Keywords

Search

Navigation